Education
About Us
Working with TipRanks
Follow Us
Nektar Therapeutics (NKTR)
NASDAQ:NKTR
Total Valuation
Nektar Therapeutics has a market cap or net worth of $148.21M. The enterprise value is $191.59M.
Market Cap$148.21M
Enterprise Value$191.59M
Share Statistics
Nektar Therapeutics has 186,103,590 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding186,103,590
Owned by Insiders1.09%
Owned by Institutions28.13%
Financial Efficiency
Nektar Therapeutics’s return on equity (ROE) is -1.96 and return on invested capital (ROIC) is -40.02%.
Return on Equity (ROE)-1.96
Return on Assets (ROA)-0.39
Return on Invested Capital (ROIC)-40.02%
Return on Capital Employed (ROCE)-0.43
Revenue Per Employee1.61M
Profits Per Employee-1.95M
Employee Count61
Asset Turnover0.32
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Nektar Therapeutics is -1.61. Nektar Therapeutics’s PEG ratio is 0.13.
PE Ratio-1.61
PS Ratio0.00
PB Ratio10.74
Price to Fair Value3.15
Price to FCF-0.73
Price to Operating Cash Flow-0.83
PEG Ratio0.13
Income Statement
In the last 12 months, Nektar Therapeutics had revenue of 98.43M and earned -118.96M in profits. Earnings per share was -0.58.
Revenue98.43M
Gross Profit67.74M
Operating Income-105.20M
Pretax Income-119.20M
Net Income-118.96M
EBITDA-86.70M
Earnings Per Share (EPS)-0.58
Cash Flow
In the last 12 months, operating cash flow was -176.87M and capital expenditures -1.31M, giving a free cash flow of -178.19M billion.
Operating Cash Flow-176.87M
Free Cash Flow-178.19M
Free Cash Flow per Share-0.96
Dividends & Yields
Nektar Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.38
52-Week Price Change-46.43%
50-Day Moving Average0.68
200-Day Moving Average0.98
Relative Strength Index (RSI)55.45
Average Volume (3m)1.80M
Important Dates
Nektar Therapeutics upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateMay 8, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
Nektar Therapeutics as a current ratio of 4.26, with Debt / Equity ratio of 730.36%
Current Ratio4.26
Quick Ratio4.26
Debt to Market Cap0.10
Net Debt to EBITDA-0.67
Interest Coverage Ratio-3.74
Taxes
In the past 12 months, Nektar Therapeutics has paid -239.00K in taxes.
Income Tax-239.00K
Effective Tax Rate<0.01
Enterprise Valuation
Nektar Therapeutics EV to EBITDA ratio is -2.88, with an EV/FCF ratio of -1.41.
EV to Sales2.54
EV to EBITDA-2.88
EV to Free Cash Flow-1.41
EV to Operating Cash Flow-1.42
Balance Sheet
Nektar Therapeutics has $218.63M in cash and marketable securities with $100.34M in debt, giving a net cash position of -$118.30M billion.
Cash & Marketable Securities$218.63M
Total Debt$100.34M
Net Cash-$118.30M
Net Cash Per Share-$0.64
Tangible Book Value Per Share$0.30
Margins
Gross margin is 74.61%, with operating margin of -106.88%, and net profit margin of -120.86%.
Gross Margin74.61%
Operating Margin-106.88%
Pretax Margin-121.10%
Net Profit Margin-120.86%
EBITDA Margin-88.08%
EBIT Margin-92.54%
Analyst Forecast
The average price target for Nektar Therapeutics is $5.10, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$5.10
Price Target Upside580.00% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast-3.24%
EPS Growth Forecast31.00%